Marchés français ouverture 5 h 11 min
  • Dow Jones

    26 659,11
    +139,16 (+0,52 %)
     
  • Nasdaq

    11 185,59
    +180,72 (+1,64 %)
     
  • Nikkei 225

    23 138,58
    -193,36 (-0,83 %)
     
  • EUR/USD

    1,1689
    +0,0011 (+0,09 %)
     
  • HANG SENG

    24 501,43
    -85,17 (-0,35 %)
     
  • BTC-EUR

    11 561,88
    +61,13 (+0,53 %)
     
  • CMC Crypto 200

    264,71
    +22,03 (+9,08 %)
     
  • S&P 500

    3 310,11
    +39,08 (+1,19 %)
     

North America Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class ; Route of Administration ; Distribution Channel ; and Country

ReportLinker
·2 min de lecture

The North American Chronic Cough market is projected to reach US$ 3,944. 89 million by 2027 from US$ 2,118. 42 million in 2019; it is estimated to grow with a CAGR of 8. 1% from 2020 to 2027. The growth of the chronic cough market is primarily attributed to rising incidences of chronic cough, growing product developments to treat chronic cough.

New York, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Chronic Cough Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class ; Route of Administration ; Distribution Channel ; and Country" - https://www.reportlinker.com/p05974391/?utm_source=GNW
More over the rising outbreak of the COVID-19 pandemic has highly affected the countries in the North American region and the chronic cough market in the region.
The developments in the pharmaceutical and biopharmaceutical industry for the drugs that can treat chronic cough are likely to lead the market growth.Additionally, there is a rise in the number of global pharmaceutical companies and several startups across the region are involved in the product development for chronic cough.

For instance, in May 2020, BELLUS Health Inc., a biopharmaceutical company, has developed novel therapeutics for the chronic cough and other hypersensitization-related disorders. The company is continuously engaged in product development and has recently conducted a virtual key opinion leader (KOL) meeting to discuss the development regarding chronic cough on 27 May 2020. Specifically, the conference covered the developmental aspects regarding the phase 2 RELIEF trial of BLU-5937 in chronic refractory cough. The company is looking forward to releasing data of clinical trials for RELIEF in June or July 2020t
In 2019, the drug class segment accounted for a larger share of the North American chronic cough market.Its growth is attributed to growing product developments to treat chronic cough.

Additionally, rising incidences of chronic cough likely to drive the growth of drug class segment in the North American chronic cough market.
A few major primary and secondary sources for the chronic cough market included in the report are Instrument, US Food and Drug Administration, and Canada Foundation of Innovation.
Read the full report: https://www.reportlinker.com/p05974391/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001